肺气肿范围对特发性肺纤维化患者系列肺功能的影响
该研究为两项IFN-γ-1b III期随机双盲安慰剂对照试验(GIPF-001和GIPF-007)的事后汇总分析,纳入有第48周数据、基线高分辨率CT图像及特定FEV1/FVC比值范围的特发性肺纤维化患者。结果显示38%的患者存在肺气肿,纤维化与肺气肿范围呈负相关(r=-0.232,P<0.001)。肺气肿范围最大四分位(28-65%)的患者第48周FVC下降幅度最小,与无肺气肿患者差异为3.32%(P=0.047)。多变量分析中,肺气肿范围≥15%与48周内FVC下降显著减少相关,但一氧化碳弥散量或复合生理指数未见此关联。作者结论认为,对于特发性肺纤维化合并肺气肿范围≥15%的患者,FVC测量可能不适用于监测疾病进展。
要点
- 特发性肺纤维化患者中38%存在肺气肿,纤维化与肺气肿范围呈负相关(r=-0.232;P<0.001)。
- 肺气肿范围最大四分位(28-65%)患者第48周FVC下降最小,与无肺气肿患者差异为3.32%(P=0.047)。
- 多变量分析中,肺气肿范围≥15%与48周内FVC下降显著减少相关,而一氧化碳弥散量或复合生理指数无此关联。
- 作者结论:FVC测量可能不适用于监测肺气肿范围≥15%的特发性肺纤维化患者的疾病进展。
适用人群与场景
- 特发性肺纤维化患者,来自GIPF-001和GIPF-007两项III期随机双盲安慰剂对照试验的汇总数据。
- 纳入标准:有第48周数据、基线高分辨率CT图像,且FEV1/FVC比值<0.8或>0.9(GIPF-007中<0.7或>0.9),以及随机选取的比值0.8-0.9和0.7-0.8的患者。
研究设计与关键结果
- 研究类型:两项III期随机双盲安慰剂对照试验(GIPF-001和GIPF-007)的事后汇总分析。
- 人群:特发性肺纤维化患者,有第48周数据及基线高分辨率CT图像,FEV1/FVC比值符合上述标准。
- 干预与对照:IFN-γ-1b vs 安慰剂(试验原始干预),本分析按肺气肿范围分组。
- 主要结果:38%的患者存在肺气肿;纤维化与肺气肿范围负相关(r=-0.232;P<0.001)。
- 四分位分析:肺气肿范围最大四分位(28-65%)患者第48周FVC下降最小,与无肺气肿患者差异为3.32%(P=0.047)。
- 多变量分析:肺气肿范围≥15%与48周内FVC下降显著减少相关(vs 无肺气肿或肺气肿<15%);一氧化碳弥散量或复合生理指数无此关联。
证据类型、等级与局限
- 证据类型:两项随机双盲安慰剂对照试验的事后汇总分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,FVC测量可能不适用于监测肺气肿范围≥15%的特发性肺纤维化患者的疾病进展。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Patients with idiopathic pulmonary fibrosis and emphysema may have artificially preserved lung volumes.
OBJECTIVES: In this post hoc analysis, we investigated the relationship between baseline emphysema and fibrosis extents, as well as pulmonary function changes, over 48 weeks.
METHODS: Data were pooled from two phase III, randomized, double-blind, placebo-controlled trials of IFN-γ-1b in idiopathic pulmonary fibrosis (GIPF-001 [NCT00047645] and GIPF-007 [NCT00075998]). Patients with Week 48 data, baseline high-resolution computed tomographic images, and FEV1/FVC ratios less than 0.8 or greater than 0.9 (<0.7 or >0.9 in GIPF-007), as well as randomly selected patients with ratios of 0.8-0.9 and 0.7-0.8, were included. Changes from baseline in pulmonary function at Week 48 were analyzed by emphysema extent. The relationship between emphysema and fibrosis extents and change in pulmonary function was assessed using multivariate linear regression.
MEASUREMENTS AND MAIN RESULTS: Emphysema was identified in 38% of patients. A negative correlation was observed between fibrosis and emphysema extents (r = -0.232; P < 0.001). In quartile analysis, patients with the greatest emphysema extent (28 to 65%) showed the smallest FVC decline, with a difference of 3.32% at Week 48 versus patients with no emphysema (P = 0.047). In multivariate analyses, emphysema extent greater than or equal to 15% was associated with significantly reduced FVC decline over 48 weeks versus no emphysema or emphysema less than 15%. No such association was observed for diffusing capacity of the lung for carbon monoxide or composite physiologic index.
CONCLUSIONS: FVC measurements may not be appropriate for monitoring disease progression in patients with idiopathic pulmonary fibrosis and emphysema extent greater than or equal to 15%.
参考来源
- Cottin V, Hansell DM, Sverzellati N, et al. Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017. PMID: 28657784. doi:10.1164/rccm.201612-2492OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。